Humacyte presents positive ATEV outcomes for dialysis patients, arterial trauma.

Humacyte, a biotechnology company, reported positive outcomes for dialysis patients treated with its acellular tissue engineered vessel (ATEV). Post-implantation analysis showed progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue. The ATEV demonstrated positive results for patients suffering from Steal syndrome, and durable two-year outcomes for patients treated in Ukraine conflict and female dialysis patients. Additionally, the ATEV showed results for patients treated with torso arterial trauma.